证券代码：688336 证券简称：三生国健 公告编号：2023-020 三生国健药业（上海）股份有限公司 关于新增 2023 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 次新增日常关联交易金额合计人民币 3,000.00 万元，关联董事 LOU JING、苏冬梅予以回避表决，出席会议的非关联董事一致同意该议案。 公司独立董事在董事会上发表了明确同意的独立意见，认为：公 司新增预计 2023 年度与关联人发生的日常关联交易事项符合公司日 常经营发展的需要。关联交易遵循客观公平、平等自愿、互惠互利的 原则，交易价格按照公平合理的原则参照市场价格协商确定，不存在 损害公司及股东利益，特别是中小股东利益的情形。关联交易对公司 的财务状况、经营成果不会产生任何不利影响，公司的主营业务也不 会因此类交易而对关联人形成依赖。公司董事会在审议此项涉及关联 交易的议案时，关联董事回避表决，其表决程序及过程符合法律、法 规和《公司章程》的有关规定。综上，公司独立董事同意该议案。 是否需要提交股东 ...

重要内容提示： 三生国健药业（上海）股份有限公司（以下简称"公司"）于 2023 年 8 月 24 日分别召开第四届董事会第十八次会议及第四届监事会第 十三次会议，审议通过了《关于继续使用部分暂时闲置募集资金进行 现金管理的议案》，同意公司继续使用总额度不超过人民币60,000.00 万元（包含本数）的暂时闲置募集资金进行现金管理，用于购买安全 性高、流动性好的投资产品（包括但不限于购买保本型理财产品、结 构性存款、通知存款、定期存款、大额存单、协定存款等），使用期 限自董事会审议通过之日起 12 个月内有效，在前述额度及使用期限 范围内，资金可以循环滚动使用。公司独立董事对此发表了明确同意 的独立意见，保荐机构华泰联合证券股份有限公司（以下简称"保荐 机构"）亦对本事项出具了明确的核查意见。 一、募集资金基本情况 根据中国证券监督管理委员会于 2020 年 6 月 23 日出具的《关于 同意三生国健药业（上海）股份有限公司首次公开发行股票注册的批 1 证券代码：688336 证券简称：三生国健 公告编号：2023-019 三生国健药业（上海）股份有限公司 关于继续使用部分暂时闲置募集资金进行现金管理 的公告 ...

1 证券代码：688336 证券简称：三生国健 公告编号：2023-023 三生国健药业（上海）股份有限公司 第四届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 三生国健药业（上海）股份有限公司（以下简称"公司"）第四 届监事会第十三次会议通知于 2023 年 8 月 13 日以电话、电子邮件、 专人送达等方式发出。会议于 2023 年 8 月 24 日以通讯方式召开。会 议由监事会主席曹虹女士主持，本次会议的召集与召开程序、出席会 议人员资格及议事和表决程序符合《中华人民共和国公司法》和《三 生国健药业（上海）股份有限公司章程》（以下简称"《公司章程》"） 的有关规定。 二、监事会会议审议情况 一、 监事会会议召开情况 经与会监事认真审议，并以投票表决的方式审议通过了如下决 议： （一）审议通过《关于公司 2023 年半年度报告及摘要的议案》 经审议，公司监事会认为：公司 2023 年半年度报告及摘要的编 制和审议程序符合法律、法规、《公司章程》和公司内部管理制度的 各项规定；报告的内容和格 ...

Financial Performance - The company achieved a revenue of CNY 207.34 million in Q1 2023, representing a year-on-year growth of 29.17%[9] - Net profit attributable to shareholders reached CNY 33.51 million, showing a significant increase of 9,494.39% compared to the same period last year[9] - Basic and diluted earnings per share were both CNY 0.05, reflecting a significant increase of 9,485.06%[30] - Total operating revenue for Q1 2023 reached CNY 207,340,680.29, a 29.1% increase from CNY 160,512,362.00 in Q1 2022[46] - Net profit for Q1 2023 was CNY 30,586,686.03, a significant recovery from a net loss of CNY 2,598,518.12 in Q1 2022[48] - The company reported a profit before tax of CNY 31,606,759.99 for Q1 2023, recovering from a loss of CNY 7,526,840.67 in Q1 2022[48] Revenue Segmentation - The revenue from the CDMO business surged by 623.30% year-on-year, indicating strong growth in this segment[11] - The company reported a 9.51% increase in revenue from Yisaipu and a 45.64% increase from Saiputing during the same period[11] Research and Development - The R&D investment as a percentage of revenue decreased by 5.82 percentage points, attributed to the increase in revenue compared to the previous year[22] - The company made significant clinical progress with 6 major advancements in its pipeline as of the reporting date[11] - The company received approval for clinical trials of SSGJ-611 for chronic sinusitis with nasal polyps in early April 2023[20] - A Phase III clinical study for the anti-IL-17A humanized monoclonal antibody (608) was successfully completed in early April with all subjects enrolled[32] - Research and development expenses for Q1 2023 totaled CNY 60,101,527.05, down from CNY 64,161,070.33 in Q1 2022, indicating a 6.4% decrease[46] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 31.46% compared to the previous year, primarily due to lower sales collections[22] - The net cash flow from operating activities was CNY 54,976,079.60, a decrease of 31.46% compared to the previous period[30] - In Q1 2023, the company's cash inflow from operating activities was approximately ¥241.86 million, a decrease of 17.1% compared to ¥292.03 million in Q1 2022[49] - The net cash flow from operating activities for Q1 2023 was ¥54.98 million, down 31.4% from ¥80.21 million in Q1 2022[49] - Cash and cash equivalents increased to CNY 1,435,641,921.91 from CNY 1,090,721,048.51, indicating a strong liquidity position[39] - The company experienced a net increase in cash and cash equivalents of ¥344.12 million in Q1 2023, contrasting with a decrease of ¥105.05 million in Q1 2022[51] Assets and Liabilities - Total assets decreased by 2.97% to CNY 4,947,104,734.64 from CNY 5,098,403,734.80 at the end of the previous year[30] - The total liabilities decreased from CNY 498,881,958.65 in the previous year to CNY 319,393,242.91 in the current year[46] - The total equity attributable to shareholders increased to CNY 4,636,963,819.85 from CNY 4,605,846,042.52 year-over-year[46] - Non-current assets totaled CNY 2,167,297,708.24, an increase from CNY 2,112,069,752.76, indicating ongoing investment in long-term assets[42] Market Challenges - The company is facing risks related to the uncertainty of innovative drug development and significant market competition[25] - The company highlighted the challenges in market expansion and product commercialization due to regulatory scrutiny and market acceptance issues[54] - The company is involved in CDMO business, which may expose it to legal risks and potential liabilities affecting its operations and reputation[54] - The company is focused on the successful market launch of innovative drugs, which requires effective marketing and academic promotion strategies[54]

证券代码：688336 证券简称：三生国健 公告编号：2023-009 三生国健药业（上海）股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 4 月 10 日(星期一)上午 10:00-11:30 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2023 年 3 月 31 日(星期五) 至 4 月 7 日(星期五)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮 箱 ir@3s-guojian.com 进行提问。公司将在说明会上对投资者普遍关 注的问题进行回答。 三生国健药业（上海）股份有限公司（以下简称"公司"）已于 2023 年 3 月 22 日发布公司 2022 年度报告，为便于广大投资者更全 面深入地了解公司 2022 年度经营成果 ...

Financial Performance - The company's operating revenue for 2022 was CNY 825.49 million, a decrease of 11.12% compared to CNY 928.81 million in 2021[1]. - Net profit attributable to shareholders increased by 172.99% to CNY 49.30 million from CNY 18.06 million in the previous year[1]. - The net cash flow from operating activities was CNY 233.49 million, a significant improvement from a negative cash flow of CNY -243.79 million in 2021[1]. - The basic earnings per share rose to CNY 0.08, up 166.67% from CNY 0.03 in 2021[2]. - The company's total assets increased by 4.29% to CNY 5.10 billion from CNY 4.89 billion in 2021[2]. - In 2022, the company achieved revenue of CNY 825.49 million, a decrease of 11.12% year-on-year, while net profit attributable to the parent company was CNY 49.30 million, an increase of 172.99% year-on-year[17]. Product Performance - The revenue from the core product Yisaipu decreased by 33.94% to CNY 531 million, while the innovative product Saiputing saw a revenue increase of 138.14% to CNY 159 million[2]. - The core product Yisaipu saw a revenue decline of 33.94% due to intensified market competition and reduced patient visits, while the innovative product Saiputing's sales increased by 138.14% year-on-year[17]. - The CDMO business generated sales revenue of CNY 100.25 million, a year-on-year growth of 159.81%, highlighting its importance as a new growth point for the company[17]. - The sales revenue of Yisaipu (recombinant human TNF receptor-antibody fusion protein) in China decreased by 33.94% year-on-year due to reduced patient visits and intensified market competition in the rheumatoid and ankylosing spondylitis sectors[21]. - Sales revenue of Saiputing (injection of Ininotuzumab) increased by 138.14% year-on-year, with hospital coverage exceeding 1,300, an increase of 710 hospitals compared to the previous year[24]. - The revenue of Jianipai (recombinant anti-CD25 humanized monoclonal antibody injection) grew by 45.43% year-on-year, supported by academic promotion and increased hospital sales coverage[25]. Research and Development - The company invested CNY 330 million in R&D in 2022, focusing on enhancing clinical trial efficiency and advancing core autoimmune projects[17]. - The company has 13 products in its R&D pipeline, with 17 clinical research projects ongoing, including three in Phase III trials[28]. - The company reported a total R&D investment of approximately CNY 329.63 million in 2022, a decrease of 30.35% compared to CNY 473.28 million in the previous year[90]. - The company applied for 50 new patents in 2022 and obtained 14, bringing the total effective patent applications to 207 and granted patents to 73[88]. - The company is transitioning from a fast-follow stage to a first-in-class scientific innovation stage in the innovative drug development process[86]. - The focus of R&D is shifting towards bispecific antibody drugs, which can block multiple signaling pathways for more effective treatment[86]. Market Trends and Strategies - The market for innovative drugs in the field of autoimmune diseases is rapidly expanding, with sales growth rates for IL-17 and IL-4 related biologics reaching 145% and 216% respectively in 2022[11]. - The company expects the sales of Yisaipu to stabilize and grow in 2023, with plans to expand coverage in county-level markets and promote its new water injection product[17]. - The company plans to launch a new product (301S) in 2023 and aims for significant clinical progress in multiple core projects[19]. - The company is focusing on expanding its market presence and enhancing the usage of its products in various medical fields, including traditional Chinese medicine[21]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share in the region by 2025[100]. Risk Factors - The company faces risks related to the uncertainty of innovative drug development, which has a long cycle, high investment, and low success rate[127]. - The company faces intensified competition in the TNF-α inhibitor market, with over 10 approved drugs and numerous candidates in development, risking market share and pricing pressure[129]. - Increased R&D expenditures are anticipated due to the deepening of R&D projects, which may lead to losses if R&D costs exceed profits from commercialized products[191]. - The company emphasizes the need for continuous innovation in drug development to ensure a pipeline of commercially viable products, as failure to do so could negatively impact business performance[190]. Corporate Governance and Compliance - The company received an A- rating in the latest ESG assessment, ranking in the top 6.1% of all A-share companies, reflecting its commitment to environmental, social, and governance practices[17]. - The company emphasizes quality control throughout the product development and commercialization process, maintaining a culture of compliance and quality first[72]. - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[192].

三生国健药业（上海）股份有限公司 投资者关系活动记录表 三生国健药业（上海）股份有限公司 投资者关系活动记录表 一、 调研情况 调研时间：2022 年 5 月 11 日 调研形式：2022 年中金医药健康产业论坛 - 三生国健（电话会议） 公司接待人员：副总兼董秘、证代 调研机构：中金、Prime Capital、太平金控、SGS、尚诚投资、歌斐资产管理 有限公司、中国人寿资产管理有限公司、BEST INVESTMENT CORPORATION (CIC Group)、硅港资本、植富资本、中金资本、中信保诚资产管理有限责任公司、 信达澳银、惠正投资、汇丰晋信、artisan partners、招商基金、平安证券、 陆家嘴国泰人寿保险、CCB AM、长城基金等 二、 调研主要内容 1、全面介绍公司业务发展情况（会议 PPT 详见公司官网 https://www.3s- guojian.com/investor/） 2、投资者问答 问题 1、疫情对公司的影响及公司复工复产的情况？ 1、疫情对公司的影响及公司复工复产的情况？ 答：真正意义上影响到我们应该是在三月中旬开始，但是整体来讲我们准备工 作比较充分，克服困难 ...

Financial Performance - The company's revenue for Q3 2022 was ¥186,755,665.94, representing a 25.09% increase compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2022 was ¥8,366,397.96, while the net profit for the year-to-date period decreased by 79.40% to ¥1,177,032.01[7]. - Total revenue for the first three quarters of 2022 was ¥527,354,132.76, a decrease of 16.06% compared to ¥628,020,782.36 in the same period of 2021[26]. - Net profit for the third quarter of 2022 was -¥5,995,873.26, an improvement from -¥10,550,259.89 in the same quarter of 2021[29]. - The total comprehensive income attributable to the parent company for Q3 2022 was ¥15,032,660.22, compared to ¥7,164,704.58 in Q3 2021, showing an increase[30]. Research and Development - Research and development (R&D) expenses totaled ¥72,419,985.97 in Q3 2022, a decrease of 31.39% year-on-year, and accounted for 38.78% of revenue, down 31.92 percentage points[9]. - The company focused its R&D spending on self-immune fields, leading to a reduction in expenses for other areas, which contributed to the overall decrease in R&D costs[12]. - Research and development expenses for the first three quarters of 2022 amounted to ¥216,576,998.56, a decrease of 31.85% from ¥317,787,448.27 in 2021[26]. - The company has a significant focus on R&D, with ongoing investments in new product development and market expansion strategies[20]. Assets and Liabilities - The total assets at the end of Q3 2022 were ¥5,044,377,769.75, reflecting a 3.18% increase from the end of the previous year[9]. - The total liabilities increased to ¥487,588,673.99 in 2022 from ¥349,731,365.38 in 2021, representing a growth of 39.5%[26]. - The total current assets increased to RMB 3,010,797,962.82, up from RMB 2,871,558,476.65, indicating a growth of approximately 4.9%[22]. - The total non-current assets slightly increased to RMB 2,033,579,806.93 from RMB 2,017,273,633.62, a growth of approximately 0.8%[22]. - The total equity attributable to shareholders at the end of Q3 2022 was ¥4,566,423,460.47, a slight increase of 0.55% from the previous year[9]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥140,442,228.33, indicating an increase due to improved sales collection[9]. - The net cash flow from operating activities for the first three quarters of 2022 was ¥140,442,228.33, a significant improvement from a negative cash flow of ¥148,252,249.96 in the same period of 2021[33]. - The net cash flow from investing activities for Q3 2022 was -¥399,764,887.91, compared to -¥76,069,736.51 in Q3 2021, reflecting increased investment outflows[33]. - The total cash inflow from investment activities for the first three quarters of 2022 was ¥4,657,265,367.56, significantly higher than ¥2,458,756,568.50 in the same period of 2021[33]. - The company received cash from financing activities amounting to ¥152,297,520.00 in Q3 2022, with a net cash flow from financing activities of ¥151,949,325.55[33]. Shareholder Information - The number of shareholders at the end of the reporting period was 11,861, with the largest shareholder holding 92% of the shares[16].

Financial Performance - The company's revenue for the first half of 2022 was ¥340,598,466.82, a decrease of 28.85% compared to ¥478,724,674.65 in the same period last year [29]. - The net profit attributable to shareholders for the first half of 2022 was -¥7,189,365.95, representing a decline of 132.06% from ¥22,423,120.44 in the previous year [29]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥29,058,399.49, a decrease of 517.87% compared to ¥6,953,866.90 in the same period last year [29]. - The company's operating revenue decreased by 28.85% year-on-year, primarily due to the impact of recurring pandemic conditions and intensified market competition, leading to a significant drop in sales of its core product, Yisaipu [31]. - The net profit attributable to shareholders for the reporting period was a loss of 7.19 million yuan, influenced by the decline in operating revenue and operating expenses [31]. - The company's basic earnings per share (EPS) for the first half of the year is -0.01 yuan, a decrease of 125.00% compared to the same period last year when it was 0.04 yuan [30]. - The company achieved a revenue of 340.60 million yuan in the first half of 2022, a decrease of 28.85% compared to the same period last year [79]. - The net profit attributable to the parent company was a loss of CNY 7.19 million, while the net profit after deducting non-recurring gains and losses was a loss of CNY 29.06 million [126]. Research and Development (R&D) - The company anticipates continued high R&D expenses as it deepens its pipeline projects, potentially leading to losses if R&D costs exceed profits from commercialized products [5]. - The company has established a comprehensive antibody drug R&D platform covering the entire process from drug discovery to commercialization [45]. - The company's R&D investment accounted for 43.43% of operating revenue, a decrease of 2.45 percentage points compared to the previous year [31]. - The total R&D investment for the first half of 2022 was RMB 147.93 million, a decrease of 32.65% compared to the same period last year [63]. - The proportion of R&D investment to operating income decreased from 45.88% to 43.43% year-on-year [63]. - The company has 16 antibody drugs in different stages of development, focusing on oncology, autoimmune diseases, and ophthalmology [56]. - The company has established multiple innovative research technology platforms for antibody drug development, enhancing its systematic innovation capabilities [56]. - The company is in the advanced stages of clinical trials for several drugs, including a recombinant human anti-IL-17A monoclonal antibody and a recombinant human anti-PD-1 monoclonal antibody [69][70]. Market and Competition - The core product Yisaipu's sales revenue decreased due to a 60% price drop to 127 RMB per unit as part of a procurement list, impacting overall revenue growth [5]. - The company faces significant risks in innovative drug development, including long cycles, high investment, and low success rates, which could adversely affect future performance if products do not gain market approval [5]. - The company is facing potential price reductions for Yisaipu due to increased market competition and centralized procurement risks [53]. - The company faces risks from intensified competition in the HER-2 positive biopharmaceutical market, with over 10 competing products in clinical trials [119]. - The company is addressing market competition risks by enhancing hospital coverage and implementing targeted sales strategies [118]. Product Development and Pipeline - The company has 16 antibody drugs in various stages of development, focusing on oncology, autoimmune diseases, and ophthalmology [75]. - The company is focusing on the development of innovative therapies, including the PSGL-1 product, which has the potential to enhance anti-tumor efficacy by reprogramming tumor-associated macrophages [107]. - The company is advancing its dual-specific antibody projects, which aim to improve cancer treatment efficacy by targeting multiple immune checkpoints [103][104]. - The company is developing a new pre-filled formulation of the recombinant human TNF receptor-antibody fusion protein ("301S"), expected to be approved for market in Q4 2022 after completing standard bridging experiments and other preparations in H1 2022 [89]. - The anti-IL-17A humanized monoclonal antibody ("608") has shown significant efficacy in moderate to severe psoriasis patients, outperforming placebo and comparable to existing treatments, with important milestones achieved in H1 2022 including the completion of core data analysis and design of Phase III clinical study [90]. Financial Position and Assets - The total assets at the end of the reporting period were ¥4,923,034,223.55, reflecting a 0.70% increase from ¥4,888,832,110.27 at the end of the previous year [29]. - The net cash flow from operating activities for the first half of 2022 was ¥110,578,905.71, compared to -¥171,832,696.17 in the previous year [29]. - The net assets attributable to shareholders at the end of the reporting period were ¥4,546,872,536.82, a slight increase of 0.12% from ¥4,541,562,204.33 at the end of the previous year [29]. Strategic Initiatives - The company is focused on expanding its market presence both domestically and internationally, utilizing a combination of direct sales and agency models [50]. - The company has established a commercial production base in Shanghai with a total bioreactor scale exceeding 40,000 liters, ensuring automated and information-based production processes [78]. - The company plans to enhance policy coordination and implement health poverty alleviation projects nationwide, focusing on rural areas [159]. - The company aims to improve monitoring and support mechanisms for rural patients at risk of poverty, ensuring early intervention [159]. - The company will continue to collaborate with health departments for patient screening and treatment while training grassroots medical personnel [159]. Shareholder Commitments and Governance - The commitment states that shareholders will not transfer or manage their shares for 36 months from the listing date [168]. - The company commits to a 12-month lock-up period for shares held by directors and senior management after the IPO, during which no transfers or repurchases will occur [175]. - The company emphasizes compliance with regulatory requirements and market rules during the share reduction process [181]. - The company will accept supervision from regulatory bodies and the public regarding its commitments and will bear corresponding responsibilities for any violations [200].